Scott Huntington on Muck Rack

Scott Huntington

United States
As seen in: Medium, MSN, MSN Canada, Nature, Wiley Online Library, British Pharmacological Society, Inc., JAMA (The Journal of the American Medical Association), JAMA Oncology, JAMA: Journal of the American Medical Association and
Writer. Cars, Sports, Outdoors.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Scott

Contact Scott, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rising Competition In China Forces Tesla Toward Downmarket Shift

|
By Scott Huntington
| Daily Car Blog
By Scott Huntington, April 14, 2026 Tesla is grappling with a central tension in the electric vehicle market: how to sustain sales growth in an increasingly price-driven industry without undermining the profitability that underpins its long-term strategy. Investors are responding to reports that the company is considering a smaller, lower-cost electric vehicle designed to revive demand and counter slowing momentum.
Open in Who Shared Issue with article?

Adjuvant Chemotherapy Improves Long-Term Survival in Endometrial Cancer

|
By Roman Fabbricatore, Tim Cortese, Russ Conroy, Scott Huntington
| ONCOLOGY journal Verified
The addition of adjuvant chemotherapy to radiotherapy exhibited an improvement in 10-year overall survival (OS) and recurrence-free survival (RFS) vs radiotherapy alone among patients with high-risk endometrial cancer, according to long-term findings and a post hoc analysis of the phase 3 PORTEC-3 trial (NCT00411138) published in The Lancet Oncology.
Open in Who Shared Issue with article?

Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma

|
By Roman Fabbricatore, Russ Conroy, Tim Cortese, Scott Huntington
| ONCOLOGY journal Verified
Comprehensive bridging therapy administered prior to anti-BCMA CAR T-cell therapy exhibited safety and tolerability as treatment in a small cohort of patients with relapsed/refractory multiple myeloma from a single institution, according to findings from a retrospective analysis exhibited in a poster presentation at the 2025 American Society of Radiation Oncology (ASTRO) Annual Meeting.
Open in Who Shared Issue with article?
See all 600 licensed articles (612 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified